Thomas M Habermann

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9608584/publications.pdf

Version: 2024-02-01

265	6,778	136740	71532
papers	citations	32 h-index	76 g-index

282	282	282	8068
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2006, 24, 3121-3127.	0.8	1,203
2	Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nature Medicine, 2015, 21, 922-926.	15.2	927
3	ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood, 2014, 124, 1473-1480.	0.6	401
4	Relationship between increased personal well-being and enhanced empathy among. Journal of General Internal Medicine, 2005, 20, 559-564.	1.3	335
5	Post-Transplantation Lymphoproliferative Disorders in Adults. New England Journal of Medicine, 2018, 378, 549-562.	13.9	303
6	Etiologic Heterogeneity Among Non-Hodgkin Lymphoma Subtypes: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 130-144.	0.9	265
7	Nonâ€<scp>H</scp>odgkin lymphoma subtype distribution, geodemographic patterns, and survival in the <scp>US</scp>: A longitudinal analysis of the <scp>N</scp>ational <scp>C</scp>ancer <scp>D</scp>ata <scp>B</scp>ase from 1998 to 2011. American Journal of Hematology, 2015, 90, 790-795.	2.0	221
8	The clinical spectrum of Castleman's disease. American Journal of Hematology, 2012, 87, 997-1002.	2.0	184
9	Testicular lymphoma is associated with a high incidence of extranodal recurrence. , 2000, 88, 154-161.		147
10	A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood, 2018, 132, 49-58.	0.6	130
11	Diagnosis and Management of WaldenstrÃ¶m Macroglobulinemia. JAMA Oncology, 2017, 3, 1257.	3.4	110
12	Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. Haematologica, 2020, 105, 348-357.	1.7	105
13	The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. Blood, 2015, 126, 328-335.	0.6	92
14	Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced posttransplant lymphoproliferative disorder. Liver Transplantation, 1996, 2, 375-382.	1.9	71
15	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with WaldenstrÃ¶m macroglobulinemia. Annals of Hematology, 2018, 97, 1417-1425.	0.8	71
16	Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. American Journal of Transplantation, 2021, 21, 460-474.	2.6	67
17	Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. Journal of Clinical Oncology, 2021, 39, 1329-1338.	0.8	60
18	MYD88 mutation status does not impact overall survival in WaldenstrÃ¶m macroglobulinemia. American Journal of Hematology, 2018, 93, 187-194.	2.0	57

#	Article	IF	Citations
19	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41). Oncologist, 2015, 20, 1149-1153.	1.9	52
20	Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements. Haematologica, 2018, 103, 1899-1907.	1.7	52
21	Epidemiology of marginal zone lymphoma. Annals of Lymphoma, 2021, 5, 1-1.	4.5	51
22	Primary Laryngeal Lymphoma. Laryngoscope, 1997, 107, 1502-1506.	1.1	50
23	Rituximab maintenance improves overall survival of patients with follicular lymphomaâ€"Individual patient data meta-analysis. European Journal of Cancer, 2017, 76, 216-225.	1.3	50
24	Complementary and alternative medicine use among longâ€term lymphoma survivors: A pilot study. American Journal of Hematology, 2009, 84, 795-798.	2.0	49
25	Clinical heterogeneity of diffuse large B cell lymphoma following failure of frontâ€line immunochemotherapy. British Journal of Haematology, 2017, 179, 50-60.	1.2	49
26	Smoking and Risk of Non-Hodgkin Lymphoma Subtypes in a Cohort of Older Women. Leukemia and Lymphoma, 2000, 37, 341-349.	0.6	48
27	Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement. American Journal of Transplantation, 2021, 21, 475-483.	2.6	45
28	Neurological complications of peripheral and cutaneous T-cell lymphomas. Annals of Neurology, 1994, 36, 625-629.	2.8	42
29	Personalized risk prediction for eventâ€free survival at 24 months in patients with diffuse large Bâ€cell lymphoma. American Journal of Hematology, 2016, 91, 179-184.	2.0	41
30	Ibrutinib monotherapy outside of clinical trial setting in WaldenstrÃ¶m macroglobulinaemia: practice patterns, toxicities and outcomes. British Journal of Haematology, 2020, 188, 394-403.	1.2	41
31	Role of systemic highâ€dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990â€2018. American Journal of Hematology, 2019, 94, 291-298.	2.0	40
32	Incidence of Malignancies in Patients Treated With Sirolimus Following HeartÂTransplantation. Journal of the American College of Cardiology, 2019, 73, 2676-2688.	1.2	38
33	Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. Blood Cancer Journal, 2019, 9, 73.	2.8	37
34	Nasal and Nasopharyngeal Angiocentric T-Cell Lymphomas. Laryngoscope, 1996, 106, 139-143.	1.1	33
35	Impact of MYD88^{L265P} mutation status on histological transformation of WaldenstrÃ¶m Macroglobulinemia. American Journal of Hematology, 2020, 95, 274-281.	2.0	33
36	A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL).. Blood, 2007, 110, 121-121.	0.6	31

#	Article	IF	Citations
37	Peripheral T-cell lymphoma involving the placenta. Cancer, 1992, 70, 2963-2968.	2.0	29
38	Rituximab Toxicity in Patients with Peripheral Blood Malignant B-cell Lymphocytosis. Leukemia and Lymphoma, 2001, 42, 1329-1337.	0.6	28
39	Primary systemic amyloidosis in patients with WaldenstrÃ¶m macroglobulinemia. Leukemia, 2019, 33, 790-794.	3.3	28
40	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. Leukemia, 2021, 35, 522-533.	3.3	28
41	Acute coronary syndromes in patients with active hematologic malignancies â€“ Incidence, management, and outcomes. International Journal of Cardiology, 2019, 275, 6-12.	0.8	27
42	Lack of intrafollicular memory CD4â€‰+â€‰T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. Blood Cancer Journal, 2021, 11, 130.	2.8	27
43	Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma. American Journal of Hematology, 2017, 92, 448-453.	2.0	26
44	History of autoimmune conditions and lymphoma prognosis. Blood Cancer Journal, 2018, 8, 73.	2.8	26
45	Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma. Blood, 2019, 134, 1289-1297.	0.6	26
46	Cardiac Outcomes in a Prospective Cohort of Adult Non-Hodgkin Lymphoma Survivors. Blood, 2011, 118, 2656-2656.	0.6	26
47	Dexamethasone, rituximab and cyclophosphamide for relapsedÂand/or refractory and treatmentâ€naÃ¯ve patients with Waldenstrom macroglobulinemia. British Journal of Haematology, 2017, 179, 98-105.	1.2	25
48	Predictors of symptomatic hyperviscosity in WaldenstrÃ¶m macroglobulinemia. American Journal of Hematology, 2018, 93, 1384-1393.	2.0	24
49	Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for WaldenstrÃ¶mâ€™s macroglobulinemia. Clinical and Experimental Nephrology, 2008, 12, 292-295.	0.7	22
50	Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2020, 71, 1221-1228.	2.9	22
51	High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease?. Blood Cancer Journal, 2020, 10, 5.	2.8	22
52	Marginal zone lymphoma: present status and future perspectives. Haematologica, 2022, 107, 35-43.	1.7	22
53	Cytogenetic findings in 21 cases of peripheral T-Cell lymphoma. American Journal of Hematology, 1990, 35, 88-95.	2.0	20
54	Human Pegivirus infection and lymphoma risk and prognosis: a North American study. British Journal of Haematology, 2018, 182, 644-653.	1.2	20

#	Article	IF	Citations
55	The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in nonâ€follicular indolent Bâ€cell lymphomas. American Journal of Hematology, 2019, 94, 658-666.	2.0	19
56	Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients. Blood Cancer Journal, 2020, 10, 117.	2.8	18
57	Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era. Blood Advances, 2021, 5, 1379-1387.	2.5	18
58	Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793;) Tj ETQq0 0 0 rgBT /Overlock 10	0.6	17
59	PD-1 Blockade with Pembrolizumab (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485). Blood, 2015, 126, 834-834.	0.6	17
60	Treatment of late-stage Sezary syndrome with 2-Chlorodeoxyadenosine. International Journal of Dermatology, 2002, 41, 352-356.	0.5	16
61	The association of physical activity before and after lymphoma diagnosis with survival outcomes. American Journal of Hematology, 2018, 93, 1543-1550.	2.0	16
62	Impact of Organ Functionâ€“Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?. Journal of Clinical Oncology, 2021, 39, 1641-1649.	0.8	16
63	Risk of histological transformation and therapyâ€related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma. British Journal of Haematology, 2017, 178, 427-433.	1.2	15
64	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. Lupus Science and Medicine, 2017, 4, e000187.	1.1	15
65	Detection of extranodal and spleen involvement by FDGâ€PET imaging predicts adverse survival in untreated follicular lymphoma. American Journal of Hematology, 2019, 94, 786-793.	2.0	15
66	Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era. Leukemia and Lymphoma, 2020, 61, 298-308.	0.6	15
67	Analysis and impact of a multidisciplinary lymphoma virtual tumor board. Leukemia and Lymphoma, 2020, 61, 3351-3359.	0.6	14
68	Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial. Lancet Haematology,the, 2020, 7, e490-e497.	2.2	14
69	Rapid S-Phase Determination of Non-Hodgkinâ€™s Lymphomas with the Use of an Immunofluorescence Bromodeoxyuridine Labeling Index Procedure. American Journal of Clinical Pathology, 1989, 91, 298-301.	0.4	13
70	A susceptibility locus for classical Hodgkin lymphoma at 8q24 near <scp>MYC</scp><scp>PVT</scp>1 predicts patient outcome in two independent cohorts. British Journal of Haematology, 2018, 180, 286-290.	1.2	13
71	Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma. Hematological Oncology, 2018, 36, 749-756.	0.8	13
72	Risk of cutaneous Tâ€cell lymphoma in patients with chronic lymphocytic leukemia and other subtypes of nonâ€Hodgkin lymphoma. International Journal of Dermatology, 2017, 56, 1125-1129.	0.5	12

#	Article	IF	Citations
73	Impact of metformin use on the outcomes of newly diagnosed diffuse large Bâ€cell lymphoma and follicular lymphoma. British Journal of Haematology, 2019, 186, 820-828.	1.2	12
74	Assessment of fixedâ€duration therapies for treatmentâ€naÃ¯ve <scp>WaldenstrÃ¶m</scp> macroglobulinemia. American Journal of Hematology, 2021, 96, 945-953.	2.0	12
75	Disease outcomes and biomarkers of progression in smouldering WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2021, 195, 210-216.	1.2	12
76	Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 realâ€world patients. British Journal of Haematology, 2020, 189, 661-671.	1.2	12
77	Cryptococcus neoformansinfections in patients with lymphoproliferative neoplasms. Leukemia and Lymphoma, 2019, 60, 920-926.	0.6	11
78	Post-transplant Lymphoproliferative Disorder Following Cardiac Transplantation. Frontiers in Cardiovascular Medicine, 2022, 9, 787975.	1.1	11
79	Accuracy of 18-F FDG PET/CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma â€“ tissue remains the issue. Leukemia and Lymphoma, 2017, 58, 2342-2348.	0.6	10
80	Elevated Serum Lactate in Patients With Lymphoma: It Is Not Always Infection. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 423-430.	1.2	10
81	Expression of Interferon Regulatory Factor-4 (IRF4/MUM1) Is Associated with Inferior Overall Survival In Peripheral T-Cell Lymphoma. Blood, 2010, 116, 140-140.	0.6	10
82	FCGR3A/2A polymorphisms and diffuse large Bâ€cell lymphoma outcome treated with immunochemotherapy: a metaâ€analysis on 1134 patients from two prospective cohorts. Hematological Oncology, 2017, 35, 447-455.	0.8	9
83	Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?. Leukemia and Lymphoma, 2020, 61, 318-327.	0.6	9
84	Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma. Blood Cancer Journal, 2021, 11, 8.	2.8	9
85	Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL). Blood, 2019, 134, 69-69.	0.6	9
86	Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes. Blood Advances, 2022, 6, 1350-1360.	2.5	9
87	Chronic lymphocytic leukemia (CLL) with Reedâ€“Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?. Blood Cancer Journal, 2022, 12, 18.	2.8	9
88	Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma. Leukemia and Lymphoma, 2019, 60, 2271-2277.	0.6	8
89	Impact of lymphoma survivorship clinic visit on patient-centered outcomes. Journal of Cancer Survivorship, 2019, 13, 344-352.	1.5	8
90	Relapsed/Refractory International Prognostic Index (R/<scp>Râ€IPI</scp>): An international prognostic calculator for relapsed/refractory diffuse large Bâ€cell lymphoma. American Journal of Hematology, 2021, 96, 599-605.	2.0	8

#	Article	IF	Citations
91	Outcomes in primary cutaneous diffuse large Bâ€cell lymphoma, leg type. Hematological Oncology, 2021, 39, 658-663.	0.8	8
92	Intravascular Lymphoma: Poor Outcomes May Be Improved with Aggressive Therapy.. Blood, 2005, 106, 938-938.	0.6	8
93	Combination of Lenalidomide with R-CHOP (R2CHOP) Is Well-Tolerated and Effective As Initial Therapy for Aggressive B-Cell Lymphomas - A Phase II Study. Blood, 2012, 120, 689-689.	0.6	8
94	PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485). Blood, 2016, 128, 4392-4392.	0.6	8
95	WaldenstrÃ¶m Macroglobulinemia in the Very Elderly (â‰¥75 years):Clinical Characteristics and Outcomes. Blood, 2020, 136, 44-45.	0.6	8
96	S-phase fraction by the labeling index as a predictive factor for progression and survival in low grade non-Hodgkin's lymphoma. Cancer, 1995, 76, 1059-1064.	2.0	7
97	Fulminant Hepatic Failure Secondary to Adenovirus Following Fludarabine-Based Chemotherapy for Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 2001, 42, 1145-1150.	0.6	7
98	The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project. Oncologist, 2017, 22, 1415-1418.	1.9	7
99	Outcomes of Autologous Stem Cell Transplant Consolidation in Primary Central Nervous System Lymphoma: A Mayo Clinic Experience. Biology of Blood and Marrow Transplantation, 2020, 26, 2217-2222.	2.0	7
100	Fluorodeoxyglucose-Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular Lymphoma. Oncologist, 2020, 25, 689-695.	1.9	7
101	Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria. HemaSphere, 2021, 5, e640.	1.2	7
102	Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma. Blood, 2019, 134, 121-121.	0.6	7
103	Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials. Blood Cancer Journal, 2022, 12, 1.	2.8	7
104	Efficacy of Splenectomy for Patients with Mantle Cell Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 2001, 42, 1235-1241.	0.6	6
105	A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 664-672.e2.	0.2	6
106	The association of health behaviors with quality of life in lymphoma survivors. Leukemia and Lymphoma, 2021, 62, 271-280.	0.6	6
107	Oral Tipifarnib (R115777) Has Single Agent Anti-Tumor Activity in Patients with Relapsed Aggressive Non-Hodgkin Lymphoma (NHL): Results of a Phase II Trial in the University of Iowa/Mayo Clinic Lymphoma SPORE (CA97274).. Blood, 2006, 108, 530-530.	0.6	6
108	Treatment Patterns and Outcomes of DLBCL after Failure of Front-Line Immunochemotherapy. Blood, 2015, 126, 2683-2683.	0.6	6

#	Article	IF	Citations
109	A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma. Leukemia and Lymphoma, 2018, 59, 2128-2134.	0.6	5
110	Eventâ€free survival at 24Âmonths captures central nervous system relapse of systemic diffuse large Bâ€cell lymphoma in the immunochemotherapy era. British Journal of Haematology, 2018, 183, 149-152.	1.2	5
111	Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era. American Journal of Hematology, 2021, 96, 979-988.	2.0	5
112	Body mass index and survival of patients with lymphoma. Leukemia and Lymphoma, 2021, 62, 2671-2678.	0.6	5
113	Phase I/II Study of Ipilimumab (MDX-010), an Anti-CTLA-4 Monoclonal Antibody, in Patients with Follicular Non-Hodgkin Lymphoma.. Blood, 2006, 108, 2729-2729.	0.6	5
114	A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas. Blood, 2010, 116, 287-287.	0.6	5
115	Primary Pulmonary MALT Lymphoma: Clinical Characteristics and Treatment Outcomes â€“ Single Institution Experience. Blood, 2010, 116, 4168-4168.	0.6	5
116	The Role Of Body Mass Index In Survival Outcome For Lymphoma Patients: US Intergroup Experience. Blood, 2013, 122, 3060-3060.	0.6	5
117	In-Vivo Activation Of STAT3 In Angioimmunoblastic T Cell Lymphoma, PTCL Not Otherwise Specified, and ALK Negative Anaplastic Large Cell Lymphoma: Implications For Therapy. Blood, 2013, 122, 844-844.	0.6	5
118	Utility of Progression-Free Survival at 24 Months (PFS24) to Predict Subsequent Outcome for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled on Randomized Clinical Trials: Findings from a Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 5853 Patients. Blood, 2016, 128, 3027-3027.	0.6	5
119	Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials. Blood, 2016, 128, 3034-3034.	0.6	5
120	Lenalidomide Combined with R-CHOP (R2CHOP) Overcomes Negative Prognostic Impact of ABC Molecular Subtype in Newly Diagnosed Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 3035-3035.	0.6	5
121	Current Management Concepts: Primary Central Nervous System Lymphoma, Natural Killer T-Cell Lymphoma Nasal Type, and Post-transplant Lymphoproliferative Disorder. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e354-e366.	1.8	4
122	Low Plasma Omega-3 Fatty Acid Levels May Predict Inferior Prognosis in Untreated Diffuse Large B-Cell Lymphoma: A New Modifiable Dietary Biomarker?. Nutrition and Cancer, 2018, 70, 1088-1090.	0.9	4
123	Aspirin and other nonsteroidal antiâ€inflammatory drugs, statins and risk of nonâ€Hodgkin lymphoma. International Journal of Cancer, 2021, 149, 535-545.	2.3	4
124	Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era. Blood Cancer Journal, 2021, 11, 133.	2.8	4
125	Lines of therapy before autologous stem cell transplant and <scp>CARâ€T</scp> affect outcomes in aggressive <scp>Nonâ€Hodgkin's</scp> lymphoma. American Journal of Hematology, 2021, 96, E386-E389.	2.0	4
126	Clinical Characteristics and Outcomes of an Analysis of a Single Institution Experience of the 2017 World Health Organization (WHO) Classification of Post-Transplant Lymphoproliferative Disorders (PTLD). Blood, 2018, 132, 456-456.	0.6	4

#	Article	IF	Citations
127	Lymphoma in Pregnancy: Excellent Fetal Outcomes and Maternal Survival in a Large Multicenter Analysis. Blood, 2011, 118, 94-94.	0.6	4
128	Response-Adapted Therapy for Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL)Based On Early [18F] FDG-PET Scanning: An Eastern Cooperative Oncology Group Study (E3404). Blood, 2012, 120, 687-687.	0.6	4
129	Outcomes Of Chronic Lymphocytic Leukemia Patients With Richter Syndrome. Blood, 2013, 122, 4179-4179.	0.6	4
130	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). Blood, 2016, 128, 2968-2968.	0.6	4
131	Changes in Quality of Life in Indolent Non-Hodgkin Lymphoma 3 Years after Diagnosis. Blood, 2017, 130, 917-917.	0.6	4
132	Clinical Characteristics, Prognostic Indicators, and Survival Outcomes in Intravascular Lymphoma: Mayo Clinic Experience (2003â€“2018). American Journal of Hematology, 0, , .	2.0	4
133	Hormonal and Reproductive Factors and Risk of Myeloproliferative Neoplasms in Postmenopausal Women. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 151-157.	1.1	3
134	Testicular <scp>FDGâ€PET</scp>/<scp>CT</scp> uptake threshold in aggressive lymphomas. American Journal of Hematology, 2021, 96, E81-E83.	2.0	3
135	Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia. Leukemia and Lymphoma, 2021, 62, 308-315.	0.6	3
136	Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study. Blood Cancer Journal, 2021, 11, 160.	2.8	3
137	Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database. Blood, 2019, 134, 1610-1610.	0.6	3
138	Lines of Therapy before Autologous Stem Cell Transplant (ASCT) and CAR-T Infusion Affect Outcomes in Aggressive Non-Hodgkin's Lymphoma (NHL). Blood, 2020, 136, 29-30.	0.6	3
139	Lymphocyte Count Persistence and Early Recovery Predicts Superior Survival and Is Independent of the International Prognostic Index in Patients Treated with CHOP Chemotherapy for Diffuse Large B Cell Lymphoma.. Blood, 2004, 104, 3252-3252.	0.6	3
140	Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496. Blood, 2011, 118, 1603-1603.	0.6	3
141	Primary Central Nervous System (PCNS) Post-Transplant Lymphoproliferative Disease (PTLD): An International Report of 65 Cases in the Modern Era. Blood, 2011, 118, 879-879.	0.6	3
142	Long Term Clinical Outcomes in Patients with Massive Splenomegaly and Non-Hodgkin's Lymphoma Treated with Splenectomy.. Blood, 2012, 120, 2692-2692.	0.6	3
143	Author reply. Cancer, 2000, 89, 714-714.	2.0	2
144	Images and Reflections From Mayo Clinic Heritage. Mayo Clinic Proceedings, 2002, 77, 1182.	1.4	2

#	Article	IF	Citations
145	Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular lymphoma in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular Epidemiology Resource. Leukemia and Lymphoma, 2015, 56, 2365-2372.	0.6	2
146	Bone involvement on PET/CT predicts eventâ€free survival in follicular lymphoma Grade 3B. British Journal of Haematology, 2020, 191, e41-e43.	1.2	2
147	Predictors of short-term survival in WaldenstrÃ¶m Macroglobulinemia. Leukemia and Lymphoma, 2020, 61, 2975-2979.	0.6	2
148	An Analysis of a Multidisciplinary Lymphoma Virtual Tumor Board with Regional and International Participation. Blood, 2018, 132, 2247-2247.	0.6	2
149	Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC). Blood, 2019, 134, 400-400.	0.6	2
150	Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis. Blood, 2020, 136, 7-8.	0.6	2
151	Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy Who Are Alive and Progression Free 12 Months After Diagnosis Have a Subsequent Overall Survival Similar to That of the General Population. Blood, 2012, 120, 1540-1540.	0.6	2
152	Primary Breast Diffuse Large B Cell Lymphoma: A Distinct Clinical Entity. Blood, 2012, 120, 1618-1618.	0.6	2
153	IPI24: An International Study To Create An IPI For The Event-Free Survival At 24 Months (EFS24) Endpoint For DLBCL In The Immunochemotherapy Era. Blood, 2013, 122, 362-362.	0.6	2
154	Prognostic Impact of Morphology, MYC Gene Partner and BCL2/BCL6 Translocation Status in "High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements". Blood, 2016, 128, 1750-1750.	0.6	2
155	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia. Blood, 2016, 128, 2972-2972.	0.6	2
156	A Phase I Trial of CpG-7909, Rituximab Immunotherapy, and Y90 Zevalin Radioimmunotherapy for Patients (Pts) with Previously Treated CD20+ Non-Hodgkin Lymphoma (NHL).. Blood, 2007, 110, 124-124.	0.6	2
157	Potential Pathogenetic Role of Achromobacter (Alcaligenes) Xylosoxidans in Primary Extranodal Marginal Zone Lymphoma of the Lung (BALT-Lymphoma): Update of the Results of a Retrospective Analysis on Behalf of IELSG. Blood, 2011, 118, 880-880.	0.6	2
158	The Level of Physical Activity before and after Lymphoma Diagnosis Impacts Overall and Lymphoma-Specific Survival. Blood, 2017, 130, 914-914.	0.6	2
159	Depth of Response in Waldenstrom Macroglobulinemia. Blood, 2018, 132, 4141-4141.	0.6	2
160	Central Nervous System Involvement in Peripheral T-Cell Lymphoma. Blood, 2019, 134, 5293-5293.	0.6	2
161	Impact of Novel Agents on the Outcomes of Patients with Classic Hodgkin Lymphoma That Relapsed after Autologous Stem Cell Transplant. Blood, 2021, 138, 1373-1373.	0.6	2
162	Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation. American Journal of Hematology, 2022, , .	2.0	2

#	Article	IF	Citations
163	Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e815-e825.	0.2	2
164	Images and Reflections From Mayo Clinic Heritage. Mayo Clinic Proceedings, 2003, 78, 1324.	1.4	1
165	Host genetic variation in tumor necrosis factor and nuclear factorâ€ºB pathways and overall survival in mantle cell lymphoma: A discovery and replication study. American Journal of Hematology, 2019, 94, E153-E155.	2.0	1
166	Risk for Significant Kidney Function Decline After Acute Kidney Injury in Adults With Hematologic Malignancy. Kidney International Reports, 2021, 6, 1050-1057.	0.4	1
167	Relationship between uric acid and kidney function in adults at risk for tumor lysis syndrome. Leukemia and Lymphoma, 2021, 62, 1-8.	0.6	1
168	Relapses after Achieving EFS24 in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era. Blood, 2018, 132, 454-454.	0.6	1
169	Bleomycin Use in the Treatment of Hodgkin Lymphoma (HL): Toxicity and Outcomes in the Modern Era. Blood, 2019, 134, 4038-4038.	0.6	1
170	Clinical Features and Treatment for Neurolymphomatosis in the Rituximab Era: Single Institution Experience. Blood, 2019, 134, 4129-4129.	0.6	1
171	Maximizing FDG-PET/CT Utility in Staging of Follicular Lymphoma (FL): The Role of Spleen Involvement and Bone Standardized Uptake Values. Blood, 2019, 134, 2811-2811.	0.6	1
172	Primary Parotid MALT Lymphoma: Clinical Characteristics and Treatment â€“ a Single Institution Experience. Blood, 2011, 118, 1580-1580.	0.6	1
173	Prior Rituximab Exposure Does Not Appear to Affect Time to Treatment Failure After Radioimmunotherapy. Blood, 2011, 118, 1640-1640.	0.6	1
174	CXCR4 Upregulation Is a Biomarker Of Sensitivity To Targeted Inhibition Of B-Cell Receptor Signaling In Diffuse Large B-Cell Lymphoma. Blood, 2013, 122, 631-631.	0.6	1
175	Incidence and Outcomes of Treatment Refractory Diffuse Large B-Cell Lymphoma in the Immunochemotherapy Era. Blood, 2015, 126, 3992-3992.	0.6	1
176	Everolimus Plus RCHOP-21 Is Safe and Highly Effective for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Phase I Trial NCCTG1085 (Alliance). Blood, 2015, 126, 813-813.	0.6	1
177	Vitamin D Insufficiency Is Associated with an Increased Risk of Early Clinical Failure in Follicular Lymphoma. Blood, 2016, 128, 1104-1104.	0.6	1
178	Treatment and Clinical Outcomes of High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements (Double Hit/Triple Hit Lymphomas). Blood, 2016, 128, 155-155.	0.6	1
179	Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients. Blood, 2016, 128, 4196-4196.	0.6	1
180	Similar Phenotypes Demonstrated upon Initial Diagnosis and at Time of Recurrence in Relapsed DLBCL. Blood, 2016, 128, 5299-5299.	0.6	1

#	Article	IF	Citations
181	Pretreatment Serum Cytokines Predict Early Disease Relapse and a Poor Prognosis In Diffuse Large B-Cell Lymphoma (DLBCL) Patients. Blood, 2010, 116, 991-991.	0.6	1
182	Pretreatment Serum Cytokines Predict Early Disease Relapse and A Poor Prognosis In Newly Diagnosed Classical Hodgkin Lymphoma (cHL) Patients. Blood, 2011, 118, 429-429.	0.6	1
183	Gene Risk Scores Based on Expression of 6 Genes Quanitated by Nuclease Protection Assay in Formalin Fixed Paraffin-Embedded Tissue (FFPET) Specimens From CHOP and RCHOP Treated Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Predict Outcome: An ECOG and SWOG Study. Blood, 2011, 118, 87-87.	0.6	1
184	The Absolute Monocyte Count Predicts Overall Survival In Patients Newly Diagnosed with Follicular Lymphoma. Blood, 2011, 118, 85-85.	0.6	1
185	EBV(+) Diffuse Large B Cell Lymphoma Is Infrequent in Upper Central United States and Lacks Unique Clinical Characteristics or Adverse Prognosis Compared to EBV (â^') Counterparts: Results From University of Iowa/Mayo Clinic SPORE. Blood, 2012, 120, 1604-1604.	0.6	1
186	A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study. Blood, 2013, 122, 76-76.	0.6	1
187	Concomitant Myeloproliferative Disorders (MPD) and Amyloidosis. Blood, 2016, 128, 5480-5480.	0.6	1
188	Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia. Blood, 2018, 132, 622-622.	0.6	1
189	Revised-MALT-IPI: A New Predictive Model That Identifies High-Risk Patients with Extranodal Marginal Zone Lymphoma (EMZL). Blood, 2019, 134, 4010-4010.	0.6	1
190	Parsaclisib in Combination with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Preliminary Results of a Phase 1/1b Study. Blood, 2021, 138, 1415-1415.	0.6	1
191	Clinical Validation of MCL35 in Mantle Cell Lymphoma Patients â‰¥65 Years Receiving Bendamustine-Rituximab. Blood, 2021, 138, 3517-3517.	0.6	1
192	Vaccination History and Risk of Lymphoma and Its Major Subtypes. Cancer Epidemiology Biomarkers and Prevention, 2021, , cebp.0383.2021.	1.1	1
193	Central Nervous System Involvement By Mantle Cell Lymphoma. Blood, 2021, 138, 2426-2426.	0.6	1
194	Event-Free Survival at 24 Months (EFS24) Becomes an Important Clinical Endpoint in Newly Diagnosed Mantle Cell Lymphoma in the New Era. Blood, 2021, 138, 2429-2429.	0.6	1
195	Time to Refractory Status Defines Subsets of Primary Refractory Diffuse Large B-Cell Lymphoma with Distinct Outcomes. Blood, 2021, 138, 2524-2524.	0.6	1
196	Central Nervous System (CNS) Involvement of Richter Transformation: A Single Center Experience. Blood, 2020, 136, 3-4.	0.6	1
197	Clonal Somatic Mutations Are a Biomarker for Inferior Prognosis in Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 26-27.	0.6	1
198	PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts. Blood Cancer Journal, 2022, 12, 78.	2.8	1

#	Article	IF	Citations
199	ASH 2009 meeting reportâ€"Top 10 clinically oriented abstracts in lymphoma. American Journal of Hematology, 2010, 85, 280-283.	2.0	0
200	Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes. , 2021, 5, 200-217.		0
201	Epstein Barr Virusâ€"Negative Lymphoplasmacytic Proliferation Limited to the Renal Allograft: A Unique Presentation of a Rare Disease. Kidney International Reports, 2021, 6, 2223-2227.	0.4	0
202	Hiding in (not so) plain sight: Spontaneous tumor Lysis syndrome due to intravascular large B cell lymphoma. American Journal of Hematology, 2022, 97, 151-159.	2.0	0
203	Prognostic Factors and Survival of Patients with Primary Mediastinal Large B-Cell Lymphoma.. Blood, 2005, 106, 4698-4698.	0.6	0
204	Absolute Lymphocyte Count Predicts Overall Survival in T Cell Lymphomas.. Blood, 2006, 108, 3878-3878.	0.6	0
205	Improved Survival in Patients with Peripheral T Cell Lymphoma, Unspecified Following High-Dose Therapy and Stem Cell Transplantation: A Retrospective Review of a Single Institutionâ€™s Experience.. Blood, 2006, 108, 3062-3062.	0.6	0
206	Prevalence of Post-Transplant Lymphoproliferative Disorder with Monoclonal Gammopathy of Unknown Significance in Patients Undergoing Kidney Transplantation.. Blood, 2007, 110, 4778-4778.	0.6	0
207	Pre Transplantation MGUS and Transformation to Multiple Myeloma in Kidney Transplantation: A Single Center Experience.. Blood, 2007, 110, 4779-4779.	0.6	0
208	Peripheral Blood Lymphocyte/Monocyte Ratio At Diagnosis Is Independent of the Cell of Origin in Predicting Survival in Diffuse Large B-Cell Lymphoma,. Blood, 2011, 118, 3652-3652.	0.6	0
209	Utility of Stem Cell Collection in Anticipation of Future Need for Autologous Stem Cell Transplant in Follicular Lymphoma Patients. Blood, 2011, 118, 1926-1926.	0.6	0
210	Risk of Transformation of Follicular Lymphoma to High Grade Lymphoma After Radioimmunotherapy: A Prospective Observational Single Institutional Experience. Blood, 2011, 118, 1572-1572.	0.6	0
211	Peripheral Blood Lymphocyte/Monocyte Ratio At Diagnosis and Survival in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma,. Blood, 2011, 118, 3642-3642.	0.6	0
212	The Mutational Landscape of Diffuse Large B Cell Lymphoma. Blood, 2011, 118, 259-259.	0.6	0
213	Diffuse Large B-Cell Transformation in Nodular Lymphocyte Predominant Hodgkin Lymphoma: Incidence, Risk Factors and Outcomes After a Forty-Year Experience From a Single Institution. Blood, 2012, 120, 1525-1525.	0.6	0
214	Peripheral Blood Absolute Lymphocyte/Monocyte Ratio At Diagnosis Is Independent of the Interim Positron-Emission Tomography in Predicting Progression-Free Survival and Time to Progression in Classical Hodgkin Lymphoma (HL). Blood, 2012, 120, 1527-1527.	0.6	0
215	Impact of Obesity and Genetic Variation in Energy Balance and Metabolism Genes On Prognosis in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). Blood, 2012, 120, 684-684.	0.6	0
216	A Structural Basis for p53-Deficiency, Deregulated Cell Cycle and Unfavorable Outcome in Diffuse Large B-Cell Lymphoma. Blood, 2012, 120, 1534-1534.	0.6	0

#	Article	IF	Citations
217	Differences in Outcomes in Males and Females with Diffuse Large B-Cell Lymphoma with Induction Rituximab and Follicular Lymphoma Treated with Maintenance Rituximab. Blood, 2012, 120, 3705-3705.	0.6	0
218	Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era. Blood, 2012, 120, 149-149.	0.6	0
219	Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI. Blood, 2012, 120, 1563-1563.	0.6	0
220	Host Genetics and Risk of Cardiovascular Disease in a Prospective Cohort of Adult Non-Hodgkin Lymphoma Survivors. Blood, 2012, 120, 1573-1573.	0.6	0
221	Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During ABVD Treatment Cycles Predicts Clinical Outcomes in Classical Hodgkin Lymphoma (HL).. Blood, 2012, 120, 2634-2634.	0.6	0
222	Prognostic Value of Six Germline Single Nucleotide Polymorphisms At the REL, HLA-DRA, GATA3 and PVT1 Loci Identified in a Classical Hodgkin Lymphoma Genome-Wide Association Study: A Meta-Analysis of 601 Patients for Progression-Free Survival From Two Independent Studies. Blood, 2012, 120, 3637-3637.	0.6	0
223	CXCR5 Polymorphisms in Non-Hodgkin Lymphoma (NHL) Risk and Prognosis.. Blood, 2012, 120, 2702-2702.	0.6	0
224	Complement Factor H Related Protein 1 (CFHR1) Serum Level Correlates With Event-Free Survival In Follicular Lymphoma Patients Treated With Rituximab. Blood, 2013, 122, 4288-4288.	0.6	0
225	Tumor Monocyte Cross Talk Promotes Chemotherapy Resistance In Lymphoma. Blood, 2013, 122, 1774-1774.	0.6	0
226	A Meta-Analysis Of Hodgkin Lymphoma Reveals 19p13.3 (TCF3) As a Novel Susceptibility Loc. Blood, 2013, 122, 626-626.	0.6	0
227	GATA-3 Expression Promotes IL-10 Production, Alternative Macrophage Polarization, and Identifies a Subset Of High-Risk PTCL, NOS. Blood, 2013, 122, 841-841.	0.6	0
228	Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During RCHOP Treatment Cycles Predicts Clinical Outcomes In Diffuse Large B-Cell Lymphoma. Blood, 2013, 122, 4306-4306.	0.6	0
229	Study of the Subclonal Mutations in Primary Diffuse Large B-Cell Lymphoma. Blood, 2015, 126, 131-131.	0.6	0
230	Lymphocyte-to-Monocyte Ratio at Diagnosis and Survival in De Novo Double/Triple Hit Diffuse Large B-Cell Lymphoma. Blood, 2015, 126, 3885-3885.	0.6	0
231	Event-Free Survival at 12 Months and Subsequent Overall Survival in Patients with Peripheral T-Cell Lymphoma. Blood, 2015, 126, 1501-1501.	0.6	0
232	Natural History of Central Nervous System Relapse in Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era. Blood, 2015, 126, 1456-1456.	0.6	0
233	Outcomes of DLBCL Patients Entering Surveillance (without maintenance) after Immunochemotherapy in a Large Observational Study. Blood, 2016, 128, 3036-3036.	0.6	0
234	Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. Blood, 2016, 128, 1810-1810.	0.6	0

#	Article	IF	Citations
235	Lenalidomide Plus R-CHOP (R2CHOP) in Patients with Follicular Lymphoma: Data from a Phase 1/2 Study. Blood, 2016, 128, 5322-5322.	0.6	0
236	No Association of EBV or Immunosuppression Status with Outcomes in US Patients with Diffuse Large B-Cell Lymphoma Treated in the Immunochemotherapy Era. Blood, 2016, 128, 107-107.	0.6	0
237	Non-Diffuse Large B-Cell Primary Central Nervous System Lymphoma. Blood, 2018, 132, 4208-4208.	0.6	0
238	WaldenstrÃ¶m Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. Blood, 2019, 134, 1532-1532.	0.6	0
239	Characteristics of Patients with Relapsed/Refractory Burkitt Non-Hodgkin Lymphoma (NHL): Impact on the Feasibility of CAR-T Cell Therapy. Blood, 2019, 134, 5352-5352.	0.6	0
240	Impact of Acute Kidney Injury Following Diagnosis of Aggressive Lymphoma or Acute Leukemia on Long-Term Kidney Outcomes. Blood, 2019, 134, 1628-1628.	0.6	0
241	Inferior Outcomes for Older Patients in the Adolescent and Young Adult (AYA) Population with Burkitt Lymphoma Treated with Intensive Immunochemotherapy: An International Study of 108 Patients. Blood, 2019, 134, 4113-4113.	0.6	0
242	Genetic Risk Factors for Cardiovascular Disease in Adult Lymphoma Patients. Blood, 2019, 134, 5215-5215.	0.6	0
243	Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Blood, 2019, 134, 919-919.	0.6	0
244	Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse. Blood, 2019, 134, 923-923.	0.6	0
245	Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways. Blood, 2019, 134, 1480-1480.	0.6	0
246	Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era. Blood, 2019, 134, 422-422.	0.6	0
247	Follicular Lymphoma Tumor-Cell Transcriptional Programs Associate with Distinct Somatic Alterations and Tumor-Immune Microenvironments. Blood, 2021, 138, 1327-1327.	0.6	0
248	Influence of Treatment Facility Type and Annual Patient Volume on Overall Survival in Patients with Mantle Cell Lymphoma: A National Cancer Database Analysis. Blood, 2021, 138, 1348-1348.	0.6	0
249	Long Term Follow up of the Resort Study (E4402): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma. Blood, 2021, 138, 815-815.	0.6	0
250	Characteristics, Management and Outcomes of Patients with Intravascular Lymphoma: A Mayo Clinic Experience. Blood, 2021, 138, 1452-1452.	0.6	0
251	PET2 Response Associated with Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of Two Independent Prospective Cohorts. Blood, 2021, 138, 2508-2508.	0.6	0
252	Impact of Double Hit Lymphoma and Cell of Origin in the Risk of Central Nervous System Relapse in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 1439-1439.	0.6	0

#	Article	IF	Citations
253	Integration of Tumor Transcriptomic, Genomic, and Immune Profiles Reveals Distinct Populations of Low-Grade B-Cell Lymphomas with Poor Outcome. Blood, 2021, 138, 808-808.	0.6	0
254	Global Transcriptional States of Follicular Lymphoma B Cells Highlight Distinct Groups of Tumor Identity Associated with Somatic Alterations and Tumor Microenvironment. Blood, 2020, 136, 21-22.	0.6	0
255	Long-Term Results of the Treatment of Persons with Hodgkin's Lymphoma in a Resource-Constrained Setting: Real-World Data from a Single Center. Blood, 2020, 136, 33-34.	0.6	0
256	Body Mass Index and Survival of Patients with Lymphoma. Blood, 2020, 136, 2-3.	0.6	0
257	Causes of Death in Non-Follicular Indolent B-Cell Lymphoma in the Rituximab Era. Blood, 2020, 136, 36-37.	0.6	0
258	The Expression of Chromosome Region Maintenance Protein 1 (CRM1) in Large Cell Lymphoma. Blood, 2020, 136, 39-40.	0.6	0
259	High Dimensional Tissue-Based Spatial Analysis of the Tumor Microenvironment of Follicular Lymphoma Reveals Unique Immune Niches inside Malignant Follicles. Blood, 2020, 136, 17-18.	0.6	0
260	Lenalidomide/RCHOP (R2CHOP) Produces High Response Rates and Overall Survival in New, Untreated Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma- Results from MC078E. Blood, 2020, 136, 47-48.	0.6	0
261	Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study. Blood, 2020, 136, 45-46.	0.6	0
262	Beyond Mortality: Health-Related Quality of Life in Adolescent and Young Adult Patients with Lymphoma: A Longitudinal Study. Blood, 2020, 136, 7-8.	0.6	0
263	Quality of Life after Diagnosis in Survivors of Aggressive Lymphomas. Blood, 2020, 136, 15-16.	0.6	0
264	Images and reflections from Mayo Clinic heritage. Mayo Clinic Proceedings, 2002, 77, 964.	1.4	0
265	Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care. JCO Oncology Practice, 2022, , OP2100789.	1.4	0